Metformin/Remogliflozin etabonate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Metformin/Remogliflozin etabonate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Metformin/Remogliflozin etabonate can convert its Small molecule drug profile and PRKAB1 x SGLT2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Metformin/Remogliflozin etabonate (query alias: Metformin/Remogliflozin etabonate) |
|---|---|
| Modality / target | Small molecule drug; PRKAB1 x SGLT2; PRKAB1 activators, SGLT2 inhibitors |
| Highest global status | Approved |
| Originator | Glenmark Pharmaceuticals Ltd. |
| Active developers | Glenmark Pharmaceuticals Ltd. |
The MCP disease footprint includes Diabetes Mellitus, Type 2. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07696806 | Phase 4 | Enrolling by invitation | 80 | Change in Melasma Area and Severity Index (MASI) Score |
| ChiCTR2600128323 | Phase 4 | Completed | 34 | clinical remission of type 2 diabetes |
| NCT07724132 | Phase 3 | Recruiting | 1200 | Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) score |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase II Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia and Untreated CLL Patients With Genomic Deletion 11q
Phase 2; n=37; evaluation: not stated. Reported fields: -; -; TTF(Median) = 0.80 years (95% Confidence Interval, 0.53 - NA)
A Phase 1, Single-Center, Repeat-Dose, Open-Label, Fixed-Sequence Drug-Drug Interaction Study of ZX008 in Healthy Male Or Female Study Participants 18 To 55 Years Of Age
Phase 1; n=22; evaluation: not stated. Reported fields: Maximum Concentration (Cmax) of Midazolam Alone and in Combination With ZX008 at Steady State(Geometric Mean) = 8.203 nanograms per milliliter (ng/mL) (Geometric Coefficient of Variation, 40.6); Maximum Concentration (Cmax) of Midazolam Alone and in Combination With ZX008 at Steady State(Geometric Mean): Geometric Least Square Mean (GLSM) Ratio = 0.7854(90% CI, 0.6893 - 0.8949); Maximum Concentration (Cmax) of Midazolam Alone and in Combination With ZX008 at Steady State(Geometric Mean): Geometric Least Square Mean (GLSM) Ratio = 0.7854(90% CI, 0.6893 - 0.8949)
2875-LB: Effectiveness and Safety of Adjunctive Therapy in Classic Type 1 Diabetes: A Real-World Cohort Study
Not Applicable; n=312; evaluation: Positive. Reported fields: HbA1c <7%: OR = 1.73, P-Value = 0.03; HbA1c <7%: OR = 1.73, P-Value = 0.03
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Metformin/Remogliflozin etabonate addresses Diabetes Mellitus, Type 2. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2022-02-08 | A collaboration between Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, the National Cancer Institute and Fox Chase Cancer Center has shown the diabetes drug metformin may also be helpful against prostate cancer. In the study, published in the journal Prostate Cancer and Prostatic Diseases, the team found that 40% of patients showed reductions in prostate specific antigen (PSA), a well-known cancer biomarker, after eight weeks of treatment. | Phase 3 | Financial terms not disclosed |
| 2019-10-11 | GC Pharma to promote Merck's Glucophage in the Korean market for diabetes treatment. | Approved | Financial terms not disclosed |
| 2019-10-11 | GC to market Merck's diabetes treatment | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 24 July 2026. Counts and status fields may change as source records update.
